Sport Integrity Australia acknowledges that Australian Athletics has imposed a 12-month period of Ineligibility on athlete Olufemi Komolafe for the Anti-Doping Rule Violations (ADRVs) of Presence and Use of a Prohibited Substance.
Mr Komolafe returned an Adverse Analytical Finding from an In-Competition doping control test on 6 April 2026.
Mr Komolafe’s sample was analysed at the Australian Sports Drug Testing Laboratory, part of the National Measurement Institute, and the presence of D-Amfetamine/Dextroamfetamine, was detected.
D-Amfetamine/Dextroamfetamine is listed under Class S6.A (Non-Specified Stimulants) of the World Anti-Doping Code – International Standard – Prohibited List 2026.
D-Amfetamine/Dextroamfetamine is classed as a Non-Specified Substance and prohibited In-Competition only.
In accordance with Article 10.2.1 of the Australian National Anti-doping Policy 2021 (ANADP), Mr Komolafe established that the ADRVs were not committed intentionally.
Mr Komolafe also received a reduction to his sanction on the basis of No Significant Fault or Negligence under Article 10.6 of the ANADP.
|
Our latest news, resources, podcasts, courses and webinars:
|
Australian Athletics has imposed a 12-month period of Ineligibility, backdated to the date of his Provisional Suspension being 2 July 2026.
In accordance with Articles 10.1 and 10.10 of the ANADP, any medals, points or prizes obtained by Mr Komolafe from 6 April 2026 onwards, shall be forfeited.
This will include the prize money Mr Komolafe won in the 2026 Stawell Gift Final.
Mr Komolafe is ineligible to participate in any sports that have adopted a World Anti-Doping Code compliant anti-doping policy until 11:59pm 1 July 2027.
He is also not permitted to compete in a non-signatory professional league, or event organised by a non-signatory International or National level event organisation.
Mr Komolafe’s matter is published on the SIA Violations List in accordance with section 19A of the Sport Integrity Australia Act 2020 (Cth) and Article 14.3 of the ANADP.
Additional information on the Prohibited Substance
D-Amfetamine/Dextroamfetamine is a stimulant drug commonly used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Stimulant medications, such as:
- Methylphenidate (for example Ritalin, Concerta)
- Dexamphetamine and:
- D-Amfetamine/Dextroamfetamine (for example Vyvanse)
are prohibited In-Competition and require a Therapeutic Use Exemption (TUE).
Athletes must have a formal diagnosis, relevant documentation and a valid prescription for stimulant medications to be considered for a TUE.
Sport Integrity Australia recommends you check all your substances before you take them on the Sport Integrity App.